CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
The REACH project develops a novel bioreactor system for the production of hematopoietic and mesenchymal stem cells. This technology aims to enable efficient, large-scale cell culture outside cleanroom environments, facilitating advancements in cell therapies.
The REACH-project is a direct result of the FP7 StemExpand project, which aimed at the expansion and engraftment of hematopoietic and mesenchymal stem cells (MSC) for clinical use.
The results of these research activities show that a novel, closed and controlled bioreactor can be developed to grow clinically relevant numbers (>400 million) of MSCs. XPand Biotechnology BV(NL) [bioreactor development, technology valorization], Aber Instruments ltd (UK)[biomass sensor] and PreSens Precision Sensing…
Leiden University Medical Center
ACADEMISCH ZIEKENHUIS LEIDEN
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Netherlands, Bilthoven
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
United Kingdom, ABERSYSTWYTH
Type: Company (for-profit)
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
PRESENS PRECISION SENSING GMBH
Germany, Regensburg
Type: SME
Activity type: Private for-profit entities (excluding Higher or Secondary Education Establishments)
SME: Yes
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
Guests see up to 5 sectors.
